Exploring New Pathways and Emerging Data for Better Control and Management in the Personalized Treatment of Severe Asthma

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2019 to june 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Sanofi Genzyme and Regeneron Pharmaceuticals

Approximately 26 million Americans suffer from asthma with the prevalence of severe asthma being 10% of the asthmatic population. The goal of treatment strategies and controlling a patient’s asthma, preventing the symptoms, and minimizing adverse effects has shifted within the last few years. Today, there is more of an approach to implementing a personalized treatment plan as a key component to patient adherence and overall asthma control. One of these treatment plans includes using pharmacologic management through inhaled corticosteroids (ICS), long-acting beta-2 agonists, theophylline, and leukotriene modifiers. And while these are helping, several new therapies, such as anti-immunoglobulin E and anti-IL- antibodies, are aiming to control and treat asthma, which could improve the lives of patients with uncontrolled persistent asthma. More recent studies and clinical data show that new treatments such as biologics and injectables are set to become available and could help improve lung function, reduce severe exacerbations and decrease rescue bronchodilator use. Patient adherence also plays a key role in satisfaction with a personalized treatment plan. Clinicians can improve patients’ inhaler technique by assessing for and correcting inhaler errors on a regular basis; however, evidence suggests that many clinicians do not perform this guideline-recommended assessment. These new options will also reduce the number of hospital visits and ultimately reduce cost. Patient nonadherence and poor inhaler technique have been linked to higher rates of uncontrolled asthma, with concomitant increases in disease burden and healthcare utilization. With all the recent advances in therapeutic options it is being shown a personalized treatment plan needs to be put in the management strategy.

Upon completion of this activity, participants will be able to:

  • Analyze the pathophysiology of severe asthma, including the disease subtypes and molecular targets for new biologic medications

  • Describe the safety and efficacy of new and emerging therapies for patients with poorly controlled severe asthma, including the role of inflammatory mediators

  • Examine appropriate plans for asthma self-management to include proper inhaler use and technique to provide appropriate delivery of medication

  • Evaluate personalized treatment plans for patients with severe asthma based on past treatment responses, appropriate biomarkers, and exacerbation risks

  • Apply evidence-based guidelines to personalized treatment plans for patients with severe asthma that include shared decision making and promoting treatment adherence

Faculty: David I. Bernstein, MD
Professor of Medicine
Division of Immunology, Allergy and Rheumatology
University of Cincinnati College of Medicine


Dr. Bernstein serves on an advisory board for ALK and GlaxoSmithKline. He serves as a consultant for Aquestive, AbbVie and Guidepoint. He has received grant/research support from AstraZeneca, GlaxoSmithKline, Glenmark, Gossmaer, Leo Pharma, Novartis and Pearl. He serves on the speaker's bureau for ALK. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Sanofi Genzyme and Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue